标题
HIV-Associated Lipodystrophy: Impact of Antiretroviral Therapy
作者
关键词
Visceral Adipose Tissue, Atazanavir, Darunavir, Raltegravir, Etravirine
出版物
DRUGS
Volume 73, Issue 13, Pages 1431-1450
出版商
Springer Nature
发表日期
2013-09-03
DOI
10.1007/s40265-013-0108-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1
- (2013) Eric S. Daar ANNALS OF INTERNAL MEDICINE
- Efficacy and Safety of Lersivirine (UK-453,061) Versus Efavirenz in Antiretroviral Treatment–Naive HIV-1–Infected Patients
- (2013) Pietro Vernazza et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection
- (2013) Andrew Zolopa et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) Jürgen K. Rockstroh et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine
- (2013) J. I. Bernardino et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
- (2013) Francois Raffi et al. LANCET
- Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials
- (2012) Calvin J. Cohen et al. AIDS
- A Randomized Trial of Raltegravir Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor in HIV-Infected Women with Lipohypertrophy
- (2012) Jordan E. Lake et al. AIDS PATIENT CARE AND STDS
- A Switch in Therapy to a Reverse Transcriptase Inhibitor Sparing Combination of Lopinavir/Ritonavir and Raltegravir in Virologically Suppressed HIV-Infected Patients: A Pilot Randomized Trial to Assess Efficacy and Safety Profile: The KITE Study
- (2012) Ighovwerha Ofotokun et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Metabolic Effects of Darunavir/Ritonavir Versus Atazanavir/Ritonavir in Treatment-Naive, HIV Type 1-Infected Subjects over 48 Weeks
- (2012) Judith A. Aberg et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Intensification of Antiretroviral Therapy through Addition of Enfuvirtide in Naive HIV-1-Infected Patients with Severe Immunosuppression Does Not Improve Immunological Response: Results of a Randomized Multicenter Trial (ANRS 130 Apollo)
- (2012) V. Joly et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity
- (2012) Graeme J Moyle et al. ANTIVIRAL THERAPY
- Maraviroc Once-Daily Nucleoside Analog-Sparing Regimen in Treatment-Naive Patients
- (2012) Anthony Mills et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
- (2012) Paul E Sax et al. LANCET
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
- (2012) Edwin DeJesus et al. LANCET
- Dual-Energy X-Ray Absorptiometry for Quantification of Visceral Fat
- (2012) Sanjiv Kaul et al. Obesity
- Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
- (2011) Calvin Cohen et al. AIDS
- Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection
- (2011) Rebecca Scherzer et al. AIDS
- Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection
- (2011) Richard Elion et al. AIDS
- Body composition changes after switching from protease inhibitors to raltegravir
- (2011) Adrian Curran et al. AIDS
- Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: ACTG Study A5224s
- (2011) G. A. McComsey et al. CLINICAL INFECTIOUS DISEASES
- Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK
- (2011) Jürgen K. Rockstroh et al. CLINICAL INFECTIOUS DISEASES
- Fat Tissue Distribution Changes in HIV-Infected Patients Treated with Lopinavir/Ritonavir. Results of the MONARK Trial
- (2011) Sami Kolta et al. CURRENT HIV RESEARCH
- Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients
- (2011) SME Vrouenraets et al. HIV MEDICINE
- Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial
- (2011) G. Fatkenheuer et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results
- (2011) Paul E. Sax et al. JOURNAL OF INFECTIOUS DISEASES
- Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial
- (2011) Calvin J Cohen et al. LANCET
- Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
- (2011) Jean-Michel Molina et al. LANCET
- Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
- (2011) Jan van Lunzen et al. LANCET INFECTIOUS DISEASES
- Increased epicardial adipose tissue volume in HIV-infected men and relationships to body composition and metabolic parameters
- (2010) Janet Lo et al. AIDS
- Efavirenz versus Boosted Atazanavir or Zidovudine and Abacavir in Antiretroviral Treatment–Naive, HIV‐Infected Subjects: Week 48 Data from the Altair Study
- (2010) Rebekah L. Puls et al. CLINICAL INFECTIOUS DISEASES
- The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy*
- (2010) DA Cooper et al. HIV MEDICINE
- Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1-Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study
- (2010) Jean-Michel Molina et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
- (2010) Jeffrey L Lennox et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial
- (2010) J.-L. Meynard et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Fat Mass Ratio: An Objective Tool to Define Lipodystrophy in HIV-Infected Patients Under Antiretroviral Therapy
- (2010) Paula Freitas et al. JOURNAL OF CLINICAL DENSITOMETRY
- Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection
- (2010) David A. Cooper et al. JOURNAL OF INFECTIOUS DISEASES
- HIV-associated lipodystrophy: from fat injury to premature aging
- (2010) Martine Caron-Debarle et al. TRENDS IN MOLECULAR MEDICINE
- Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients
- (2009) Takara L Stanley et al. AIDS
- Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis
- (2009) Anthony M Mills et al. AIDS
- Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial
- (2009) Anton L Pozniak et al. AIDS
- Relation between visceral fat and coronary artery disease evaluated by multidetector computed tomography
- (2009) Mateus D. Marques et al. ATHEROSCLEROSIS
- Changes in Body Composition with Ritonavir‐Boosted and Unboosted Atazanavir Treatment in Combination with Lamivudine and Stavudine: A 96‐Week Randomized, Controlled Study
- (2009) Grace McComsey et al. CLINICAL INFECTIOUS DISEASES
- Improvements in Subcutaneous Fat, Lipid Profile, and Parameters of Mitochondrial Toxicity in Patients with Peripheral Lipoatrophy When Stavudine is Switched to Tenofovir (LIPOTEST Study)
- (2009) Esteban Ribera et al. HIV CLINICAL TRIALS
- Relation of Body Composition to Body Mass Index in HIV-Infected Patients With Metabolic Abnormalities
- (2009) Tisha Joy et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Lipodystrophy and Metabolic Disorders in HIV-1-Infected Adults on 4- to 9-Year Antiretroviral Therapy in Senegal: A Case-Control Study
- (2009) Sabine Mercier et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized Comparative Trial of Continued Zidovudine/Lamivudine or Replacement With Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated HIV-1-Infected Individuals
- (2009) Martin Fisher et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
- (2009) Mari M. Kitahata et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults
- (2008) Andrew Carr et al. AIDS
- Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000–2006
- (2008) A Nguyen et al. HIV MEDICINE
- The Associations of Regional Adipose Tissue With Lipid and Lipoprotein Levels in HIV-Infected Men
- (2008) David Wohl et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population
- (2008) Krishnan Bhaskaran JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Potent HIV Protease Inhibitor, Darunavir, Does Not Inhibit ZMPSTE24 or Lead to an Accumulation of Farnesyl-prelamin A in Cells
- (2008) Catherine Coffinier et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A 96‐Week Comparison of Lopinavir‐Ritonavir Combination Therapy Followed by Lopinavir‐Ritonavir Monotherapy versus Efavirenz Combination Therapy
- (2008) D. William Cameron et al. JOURNAL OF INFECTIOUS DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation